YOLFTbeta
3billion

3billion

394800 · KQ · Healthcare / Biotechnology

6,360.00KRW-280.00 (-4.22%)

Price History

Full chart

Market Stats

Previous Close6,640.00
Open6,640.00
Day Range6,300.00 – 6,870.00
52-Week Range4,020.00 – 20,100.00
Volume530.62K
Market Cap191.84B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg5,416.50
200-Day Avg10,347.63

About

3billion, Inc. develops technology for rare disease drug discovery using bioinformatics and machine learning technology. The company focuses on developing methods for novel drug target discovery, drug candidate generation, and safety assessment. It offers genetic and biomolecular testing services related to the analysis of biologic samples of patients suspected to have rare genetic disorders, as well as provides various affiliated services to customers. The company was founded in 2016 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOChangwon Keum
  • Employees0
  • Headquarters416 Teheran-ro, Seoul, South Korea, 06193, Korea
  • Websitehttps://www.3billion.io

Leadership

  • Changwon KeumCEO & Representative Director

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue550.66M828.46M2.73B5.77B11.71B
Growth (%)-+50.45%+229.57%+111.41%+102.85%
Cost of Revenue-349.04M969.99M1.68B-
Gross Profit550.66M479.42M1.76B4.10B11.71B
Gross Margin100.00%57.87%64.47%70.96%100.00%
Operating Expense7.25B8.70B10.11B11.52B17.60B
Operating Income-6.70B-8.22B-8.35B-7.42B-5.89B
Operating Margin-1216.38%-992.68%-305.91%-128.53%-50.30%
EBITDA--2.17B-3.60B-4.86B-3.27B
EBITDA Margin--261.75%-131.95%-84.25%-27.97%
Net Income-59.10B-3.14B-5.09B-6.57B-5.41B
Net Income Margin-10733.47%-379.60%-186.50%-113.85%-46.22%
R&D2.48B2.99B3.52B3.66B-
R&D as % of Total Revenue450.87%361.31%128.95%63.47%-
Interest Expense30.61M25.93M63.41M24.59M203.28M
Interest Expense % of Total Revenue5.56%3.13%2.32%0.43%1.74%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets20.59B27.66B22.86B30.22B29.67B
Total Liabilities1.88B11.35B11.07B1.94B6.07B
Total Equity18.71B16.31B11.79B28.27B23.60B
Cash4.72B7.02B2.70B11.66B8.14B

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.63B-6.41B-4.87B-4.10B-3.56B
Investing Cash Flow--4.30B1.18B-943.98M-
Financing Cash Flow-13.00B-629.53M14.01B-
Capital Expenditure674.90M264.29M246.48M2.80B2.29B
Free Cash Flow-5.31B-6.68B-5.12B-6.90B-5.85B
FCF to OCF114.57%104.12%105.06%168.20%164.49%

Earnings

Report DateMar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------
EPS Actual-53.83-51.15-34.04-31.58-46.19-43.17
Surprise------
Timing------

Key Statistics & Ratios

Market Cap191.84B
Enterprise Value163.17B
Trailing P/E0.00
Forward P/E0.00
Price / Sales19.61
Price / Book6.22
Revenue (TTM)9.78B
Gross Profit (TTM)9.78B
EBITDA-5.14B
Profit Margin-60.99%
Operating Margin-39.28%
Return on Equity-29.21%
Return on Assets-12.29%
Shares Outstanding31.76M
Shares Float23.63M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%